Skip to content

Use of laser light in association with a gel containing hyaluronic acid and L-glutamine amino acid for the treatment and prevention of oral wounds caused by treatment with radiotherapy and chemotherapy in the head and neck region

Photobiomodulation Therapy associated with L-Glutamine and Hyaluronic Acid for the Prevention and Treatment of Oral Mucositis in patients with Head and Neck Cancer undergoing Chemoradiation Therapy: Randomized Controlled Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-6ybmgcv
Enrollment
Unknown
Registered
2022-03-27
Start date
2021-09-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Neoplasms

Interventions

Intervention: 25 patients undergoing radiochemotherapeutic treatment for head and neck cancer will receive, throughout the treatment, Photobiomodulatory Therapy with low-level laser daily (5 times a w
Active control: 25 patients undergoing radiochemotherapeutic treatment for head and neck cancer will receive, throughout the treatment, Photobiomodulatory Therapy with low power laser daily (5 times a

Sponsors

Faculdade de Odontologia da Universidade Federal de Goiás
Lead Sponsor
Faculdade de Odontologia da Universidade Federal de Goiás
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients diagnosed with oral or oropharyngeal cancer; of both sexes; over 18 years old; treated with adjuvant or exclusive radiotherapy

Exclusion criteria

Exclusion criteria: Salivary gland tumors; Sjogren's Syndrome; infectious diseases of salivary glands; palliative radiotherapy; recurrent tumors; lymphoma diagnosis; diagnosis of melanoma; diagnosis of skin cancer; inability to self-care

Design outcomes

Primary

MeasureTime frame
Primary Outcome: degree of severity of oral mucositis, evaluated according to two instruments, the scale of the World Health Organization (WHO) that takes into account symptoms and ingestion capacity and that of the National Cancer Institute (NCI) of the United States of America that takes into account the size and depth of the lesions. Both evaluations will be carried out at the following times: first consultation before the start of radiotherapy (baseline) and after the 7th, 14th, 21st and 30th RT session by an evaluator blind to the participant's group, from digital photographs and registration the participant's ingestion capacity and symptomatology. World Health Organization (WHO) scale: 0 - no changes; 1 - burning and erythema; 2 - erythema, ulcers, solid diet; 3 - confluence of ulcers, liquid diet; 4 - impossibility of oral feeding. National Cancer Institute (American) (NCI) scale. 0 - no changes; 1 - mucosal erythema; 2 - pseudomembranous plaques smaller than 1.5 cm in diameter and not contiguous; 3 – confluent pseudomembrane plates, generally contiguous plates larger than 1.5 cm in diameter; 4- necrosis and/or deep ulceration or bleeding not induced by trauma.

Secondary

MeasureTime frame
Secondary Outcome 1: The impact of oral health on quality of life will be evaluated in the following times: first consultation (baseline) and after the 7th, 14th, 21st and 30th RT session, using the OHIP-14 questionnaire. The OHIP-14 (Oral Health Impact Profile; Impact of oral health on quality of life) is a questionnaire consisting of 14 questions referring to functional limitation, physical pain, psychological discomfort, disability and physical, psychological and social incapacity. The statements were answered using the “Likert” scale (never: 0, rarely: 1, sometimes: 2, often: 3, and always: 4). Each item will be assigned a specific weight and a single index will be obtained from the sum of all OHIP-14 statements (Standard weighting method). The higher the score, the greater the impact on quality of life. It can reach a score between 0 and 56 points, and the lower the total score obtained, the smaller the impact on quality of life, therefore, the greater the satisfaction and well-being of the research participant. ;Secondary outcome 2: The report of oral mucositis symptoms will be evaluated at the times: first consultation (baseline) and after the 7th, 14th, 21st and 30th RT session, through the PROMS questionnaire (Patient Reporting Scale of Mucositis Symptoms Oral). The PROMS consists of ten questions about the symptoms reported by the patient with oral mucositis and to obtain the answers a visual analogue scale (VAS) is used. There are 10 questions with a variation of 0 – 10 in a 100 mm millimeter line without the markings, allowing the patient to mark in this spectrum between the extremes 0 cm (absence of the symptom) and 10 cm (the worst pain ever experienced by the patient, for example; or total absence of taste). Therefore, the score of each participant at each time evaluated can vary from 0 to 100 points and the higher the score, the worse the quality of life related to oral symptoms. The issues assessed are: mouth pain, difficulty speaking due to mouth

Countries

Brazil

Contacts

Public ContactRodrigo;Associação de Combate dos Santos;Goiás - ACCG

Faculdade de Odontologia da Universidade Federal de Goiás ;Hospital de Câncer Araújo Jorge - Associação de Combate ao Câncer em Goiás

rodrigowilmes@discente.ufg.br;diretoriatecnicahaj@accg.org.br+55(62)981680270;+55(62)3243-7000

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 5, 2026